Details for Patent: 8,231,573
Which drugs does patent 8,231,573 protect, and when does it expire?
Patent 8,231,573 protects AUVI-Q, EVZIO, and EVZIO (AUTOINJECTOR), and is included in three NDAs.
This patent has one hundred and six patent family members in fourteen countries.
Summary for Patent: 8,231,573
| Title: | Medicament delivery device having an electronic circuit system |
| Abstract: | Medicament delivery devices are described herein. In some embodiments, an apparatus includes a medical injector and an electronic circuit system. The medical injector includes a housing, a medicament container, and a medicament delivery member. The housing defines a first region and a second region. The first region includes the medicament container and is physically isolated from the second region. The electronic circuit system is configured to be disposed within the second region defined by the housing. The electronic circuit system is configured to output an electronic output associated with a use of the medical injector. |
| Inventor(s): | Eric S. Edwards, Evan T. Edwards, Mark J. Licata, Paul F. Meyers, David A. Weinzierl |
| Assignee: | EBAP Inc dba STREAMLINE DESIGN , kaleo Inc |
| Application Number: | US12/119,016 |
|
Patent Claim Types: see list of patent claims | Composition; Delivery; Device; Dosage form; |
Drugs Protected by US Patent 8,231,573
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kaleo Inc | AUVI-Q | epinephrine | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 201739-003 | Nov 17, 2017 | RX | Yes | No | 8,231,573 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Kaleo Inc | AUVI-Q | epinephrine | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 201739-002 | Aug 10, 2012 | BX | RX | Yes | Yes | 8,231,573 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Kaleo Inc | AUVI-Q | epinephrine | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 201739-001 | Aug 10, 2012 | BX | RX | Yes | No | 8,231,573 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,231,573
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2004325202 | ⤷ Start Trial | |||
| Australia | 2006210865 | ⤷ Start Trial | |||
| Australia | 2007245139 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
